Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile FBXW7 S462P
Therapy JQ1 + Ulixertinib
Indication/Tumor Type adult T-cell leukemia/lymphoma
Response Type sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FBXW7 S462P adult T-cell leukemia/lymphoma sensitive JQ1 + Ulixertinib Preclinical - Cell culture Actionable In a preclinical study, the combination treatment of JQ1 and Ulixertinib (BVD-523) resulted in greater decreased proliferation of adult T cell leukemia cells expressing FBXW7 S462P when compared to treatment with JQ1 alone in culture (PMID: 32907612). 32907612
PubMed Id Reference Title Details
(32907612) Loss of FBXW7-mediated degradation of BRAF elicits resistance to BET inhibitors in adult T cell leukemia cells. Full reference...